Moderna's Vaccine Protects Against Covid For At Least Six Months

Antibodies to the Covid-19 virus persist for at least six months after patients receive the second dose of Moderna Inc.’s vaccine, according to a new analysis of lab results from 33 healthy adults in the drugmaker’s phase one trial. The finding, by researchers at the National Institute of Allergy and Infectious Diseases, Emory University, Moderna and elsewhere, was published as a brief correspondence in the New England Journal of Medicine. The researchers had previously published three-month followup results from the phase 1 study in the same journal.